Metal–Organic Nanomaterials for Tumor Metabolic Blockade and Image to Increase Tumor Therapy
Source abstract
Abstract
The abnormal energy metabolism level of a tumor reduces the efficiency of chemotherapy. Metal-organic nanomaterials (MONs) with high drug loading efficiency, easy processes of synthesis, and controlled drug release have shown great potential in metabolic blocking and enhancement of tumor therapy. These metal-organic nanomedicines have been reported to modulate glycolysis or oxidative phosphorylation to provide monotherapy or combined therapies in tumorous treatments. In addition, the encapsulation or coordination of fluorescent dyes into MONs endowed them with the imaging ability of tumor metabolism. Herein, this Perspective summarizes the progress of MONs as therapeutic agents or imaging probes for application during tumor metabolic blocking or imaging, providing solid inspiration for biomedical applications of effective biomaterials. In addition, the current drawbacks of MONs for further biological applications in the future were discussed, giving stimulation of innovation and development in biomedical applications of MONs.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Molecular Science and Biomedicine Laboratory, State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering
Hunan University
School of Pharmaceutical Sciences
Guizhou University
Department of Gastrointestinal Surgery
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Funding
Department of Science and Technology of Hunan Province · National Natural Science Foundation of China
References (68)
Show source-provided references
1. 10.3322/caac.2149210.3322/caac.21492 ↗
2. 10.1186/1476-4598-12-15210.1186/1476-4598-12-152 ↗
3. 10.1016/j.addr.2019.07.01010.1016/j.addr.2019.07.010 ↗
4. 10.1002/advs.20210110110.1002/advs.202101101 ↗
5. 10.1016/j.ccr.2013.01.00510.1016/j.ccr.2013.01.005 ↗
6. 10.1016/j.ccr.2020.21336610.1016/j.ccr.2020.213366 ↗
7. 10.1021/acsnano.3c0242810.1021/acsnano.3c02428 ↗
8. 10.1016/j.apsb.2024.01.01710.1016/j.apsb.2024.01.017 ↗
9. 10.1021/acs.nanolett.2c0502910.1021/acs.nanolett.2c05029 ↗
10. 10.7150/thno.7532310.7150/thno.75323 ↗
11. 10.1038/natrevmats.2017.7510.1038/natrevmats.2017.75 ↗
12. 10.1016/j.ccr.2023.21509810.1016/j.ccr.2023.215098 ↗
13. 10.1002/smll.20231062210.1002/smll.202310622 ↗
14. 10.1039/D2CC04218E10.1039/D2CC04218E ↗
15. 10.1002/advs.20230617810.1002/advs.202306178 ↗
16. 10.1039/C5CS00234F10.1039/C5CS00234F ↗
17. 10.1016/j.ccr.2021.21435410.1016/j.ccr.2021.214354 ↗
18. 10.1021/acsnano.3c0242810.1021/acsnano.3c02428 ↗
19. 10.1021/jacs.7b1175410.1021/jacs.7b11754 ↗
20. 10.1002/advs.20210353410.1002/advs.202103534 ↗
21. 10.7150/thno.6539910.7150/thno.65399 ↗
22. 10.1002/smll.20220659210.1002/smll.202206592 ↗
23. 10.1186/s12951-022-01405-w10.1186/s12951-022-01405-w ↗
24. 10.1016/j.semcancer.2022.02.00210.1016/j.semcancer.2022.02.002 ↗
25. 10.1158/0008-5472.CAN-11-167410.1158/0008-5472.CAN-11-1674 ↗
26. 10.1021/acsnano.3c0400210.1021/acsnano.3c04002 ↗
27. 10.1002/anie.20200230610.1002/anie.202002306 ↗
28. 10.1186/s13046-020-01629-410.1186/s13046-020-01629-4 ↗
29. 10.1002/adfm.20180349810.1002/adfm.201803498 ↗
30. 10.1016/j.biomaterials.2022.12150310.1016/j.biomaterials.2022.121503 ↗
31. 10.1186/1741-7007-8-8810.1186/1741-7007-8-88 ↗
32. 10.1016/j.drup.2018.03.00110.1016/j.drup.2018.03.001 ↗
33. 10.1016/j.gde.2008.02.00310.1016/j.gde.2008.02.003 ↗
34. 10.1038/nrc334010.1038/nrc3340 ↗
35. 10.1186/1476-4598-12-15210.1186/1476-4598-12-152 ↗
36. 10.1186/s12964-015-0114-x10.1186/s12964-015-0114-x ↗
37. 10.1002/adhm.20200054910.1002/adhm.202000549 ↗
38. 10.1182/blood.202101156310.1182/blood.2021011563 ↗
39. 10.1021/acsami.0c0576310.1021/acsami.0c05763 ↗
40. 10.1038/s41467-022-32349-210.1038/s41467-022-32349-2 ↗
41. 10.1016/j.cell.2016.07.00210.1016/j.cell.2016.07.002 ↗
42. 10.1038/nrc136710.1038/nrc1367 ↗
43. 10.1002/anie.20220384310.1002/anie.202203843 ↗
44. 10.1002/advs.20230603110.1002/advs.202306031 ↗
45. 10.1002/adhm.20230452210.1002/adhm.202304522 ↗
46. 10.1126/science.aaw547310.1126/science.aaw5473 ↗
47. 10.1158/2159-8290.CD-20-084410.1158/2159-8290.CD-20-0844 ↗
48. 10.1038/nature1092710.1038/nature10927 ↗
49. 10.1002/adma.20230054810.1002/adma.202300548 ↗
50. 10.1002/adma.20240101710.1002/adma.202401017 ↗
51. 10.1002/advs.20210353410.1002/advs.202103534 ↗
52. 10.3390/biomedicines908085210.3390/biomedicines9080852 ↗
53. 10.1021/ar020080710.1021/ar0200807 ↗
54. 10.1038/s41467-021-27559-z10.1038/s41467-021-27559-z ↗
55. 10.1038/s41551-016-001010.1038/s41551-016-0010 ↗
56. 10.1038/nmat447610.1038/nmat4476 ↗
57. 10.1016/j.ccr.2020.21373910.1016/j.ccr.2020.213739 ↗
58. 10.1016/j.ccr.2024.21565610.1016/j.ccr.2024.215656 ↗
59. 10.1038/s41467-022-29586-w10.1038/s41467-022-29586-w ↗
60. 10.1016/j.ccr.2022.21441810.1016/j.ccr.2022.214418 ↗
61. 10.1021/jacs.7b0122910.1021/jacs.7b01229 ↗
62. 10.1021/acs.analchem.2c0567110.1021/acs.analchem.2c05671 ↗
63. 10.3390/cancers1501006210.3390/cancers15010062 ↗
64. 10.1016/j.chempr.2019.03.01110.1016/j.chempr.2019.03.011 ↗
65. 10.1039/D2CS00562J10.1039/D2CS00562J ↗
66. 10.1002/smll.20180216610.1002/smll.201802166 ↗
67. 10.1039/C6CC06531G10.1039/C6CC06531G ↗
68. 10.1021/jacs.7b0877210.1021/jacs.7b08772 ↗